newsfilter
← Latest News
GlobeNewswire·

Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights

Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered platform and poster